Tautomycetin diacid form

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Tautomycetin diacid form
• 英文别名: (Z)-2-[(1R)-3-[(2R,3S,4R,7S,8S,11S,13R,16E)-17-ethyl-4,8-dihydroxy-3,7,11,13-tetramethyl-6,15-dioxononadeca-16,18-dien-2-yl]oxy-1-hydroxy-3-oxopropyl]-3-methylbut-2-enedioic acid
• 化学式: C₃₃H₅₂O₁₁
• 分子量: 624.8
• InChiKey: AQLTUWTUANKXRS-OXKGMMJMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  44
• 可旋转键数：
  23
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  196
• 氢给体数：
  5
• 氢受体数：
  11

文献信息

• Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis
  申请人：RHODE ISLAND HOSPITAL

  公开号：US20150352131A1

  公开（公告）日：2015-12-10

  This application discloses compositions, devices, and methods for the prevention and treatment of osteolysis and osteoporosis. Treatment or prevention of osteolysis or osteoporosis is carried out by targeting the enzyme, Shp2 (a Src homology 2 (SH2) domain containing non-transmembrane Protein Tyrosine Phosphatase (PTP)), or proteins involved in the Shp2 signaling pathway by administering a Shp2 pathway inhibitor that inhibits fusion of pre-osteoclasts.
• [EN] COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF OSTEOLYSIS AND OSTEOPOROSIS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LA PRÉVENTION ET LE TRAITEMENT DE L'OSTÉOLYSE ET DE L'OSTÉOPOROSE
  申请人：RHODE ISLAND HOSPITAL

  公开号：WO2014113584A1

  公开（公告）日：2014-07-24

  This application discloses compositions, devices, and methods for the prevention and treatment of osteolysis and osteoporosis. Osteoporosis (OP) and periprosthetic osteolysis (PO) are skeletal disorders causing major health and economic burdens worldwide. Roughly half of all women over age 50 will experience an osteoporosis-related bone fracture. About 10 to 20% of total joint arthroplasty patients suffer from PO and require revision procedures. The drugs currently available to treat OP and PO have low efficacy and unpleasant side effects. Treatment or prevention of osteolysis or osteoporosis is carried out by targeting the enzyme, Shp2 (a Src homology 2 (SH2) domain containing non-transmembrane PTP), or proteins involved in the Shp2 signaling pathway.